loratadine bijon
bijon medica, uab - loratadinas - tabletės - 10 mg - loratadine
clozapine bijon
bijon medica, uab - klozapinas - tabletės - 100 mg - clozapine
terbinafine bijon
bijon medica, uab - terbinafinas - tabletės - 250 mg - terbinafine
sitagliptin/metformin hydrochloride teva
teva gmbh - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/850 mg - metformin and sitagliptin
sitagliptin/metformin hydrochloride teva
teva gmbh - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/1000 mg - metformin and sitagliptin
sitagliptin/metformin hydrochloride grindeks
as grindeks - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/850 mg - metformin and sitagliptin
sitagliptin/metformin hydrochloride grindeks
as grindeks - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/1000 mg - metformin and sitagliptin
vildagliptin/metformin hydrochloride elvim
sia elvim - vildagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/850 mg - metformin and vildagliptin
vildagliptin/metformin hydrochloride elvim
sia elvim - vildagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/1000 mg - metformin and vildagliptin
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , trigubas derinys terapija), kaip papildoma priemonė kartu su dieta ir fiziniais pratimais pacientams, nepakankamai kontroliuojama, jų maksimali toleruojama dozė metforminas ir sulfonilkarbamido dariniai. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.